Aytu Biopharma Inc expected to post a loss of $1.60 a share - Earnings Preview

Aytu Biopharma

11/02/2023 03:01

* Aytu Biopharma Inc  AYTU.OQ   AYTU.O  is expected to show
a rise
in quarterly revenue when it reports  results on February 14. 
    * The Englewood Colorado-based  company is expected to
report  a
14.2% increase in revenue to $26.4 million from $23.13 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aytu Biopharma Inc
is for
a loss of $1.60 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aytu
Biopharma
Inc is $110​, above​ its last closing price of $3.22. ​​​

This summary was machine generated February 11 at 03:01 GMT. 
All figures in US dollars  unless otherwise stated